icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
Voir aussi
Décision d'accès précoce
14/11/2024
eNrdWFtv2jAUfudXoLw7CZdymQLVxtoNqdUYLdq0l8o4BzAzceoL0P36OQnd6JSoq6lf+oKMHX/n2D7fd44dne83rL4FISlPBl7DD706JITHNFkOvNntJep558NatMZbfPRZ1w/9RtOrE4alHHjZqD8HnEj/+/XVRzDzQXjDWj3i8zUQ9eQ7rSjzP2O5usZp9k092nIa1zegVjweeKlWeW89kkoYL4Y7Ln7KFBOIgkPP8ej6rn3cHwUZ2H+gagniCifLUtCFsMIkWghI1AgrWHLxUOFvywqbyilIrgWBCVarieBbGkNc7j1mEqyMLHbxDYgtA5UZKQUP1mQjrcDxGu+ncD8ud/q9GR2pvUIhanQ7rVa71T/rdHsdK1PiaKvKT8EsIkjvWmdnYb/bDxYiiIHQLLhRgpphs43CZjcMYhJI2KBYo0aIOFF8LqAYNl2EMwZLQDEghtEKawXI/HBBVd4pcWIaKRfKNJCAhZYoRpgQkCgVhiPkca5MjXHM8nk6pXsTQ3mD6Q2eW0bLJLPLHMUJlaOnoe7IjoD7Z+MxpjJl+MFfy9R2q7DAZhiEESR3C8lWcCuMRDKzZ//gJ5qx4IVezw4C5sjjTB9HXCeqQscup7YbMeKGF/vqE7WTXrU/xCIF+Xqwv3hSnnYmes4osRVZI4MapJpNx9Ua+7bl6QOWMBPu9OkbTWK+k6+ve8dx5sj7/ExYOSi5a/a67V6nZU3qHyakK3LwhRY8hcDoIZWnyNw4WfBTBc6wpBzqkSNvmB55bcoJZlBRnSJL9TW8eCymnTHPHauLgVLQTxe3tgH7VYN4uMn/lkLTePAn1OxSk4t8Z+hR6fjLyVYojpN7ixblSrZSKpXvgmC32/krLAu++YbKbz/3HRVA7u5xTqqsouosMogj1+dFYfCymLHl/nN12Kl3i8P8wx2m1IYSGk44iyJNOBPz8cXr54e/Fwtnbk+e6Jk7M/klACujTa5KQT0vRTwtI5lzTS6FEYgviwWteFerjMsoKN70hrUoyN7zhrXfo2yxfQ==
n2bpDtnjh4VcEbk6